Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 323

1.

Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study.

Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM.

J Clin Psychiatry. 2003 Jul;64(7):785-92.

PMID:
12934979
2.

Controlled-release paroxetine in the treatment of patients with social anxiety disorder.

Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L.

J Clin Psychiatry. 2004 Feb;65(2):222-9.

PMID:
15003077
3.

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

Liebowitz MR, Mangano RM, Bradwejn J, Asnis G; SAD Study Group.

J Clin Psychiatry. 2005 Feb;66(2):238-47.

PMID:
15705011
4.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
5.

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.

Davidson JR, Bose A, Korotzer A, Zheng H.

Depress Anxiety. 2004;19(4):234-40.

PMID:
15274172
6.

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD.

J Clin Psychiatry. 2002 Jan;63(1):66-74.

PMID:
11838629
7.

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

Liebowitz MR, Gelenberg AJ, Munjack D.

Arch Gen Psychiatry. 2005 Feb;62(2):190-8.

PMID:
15699296
8.

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.

Montgomery SA, Nil R, Dürr-Pal N, Loft H, Boulenger JP.

J Clin Psychiatry. 2005 Oct;66(10):1270-8.

PMID:
16259540
9.

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment.

Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, Johnston DC, Lavallie YJ, Nandy S, Pecknold JC, Hadrava V, Lane RM.

J Clin Psychopharmacol. 2000 Dec;20(6):636-44.

PMID:
11106135
10.

Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression.

Ravindran AV, Guelfi JD, Lane RM, Cassano GB.

J Clin Psychiatry. 2000 Nov;61(11):821-7.

PMID:
11105734
11.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
13.

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T.

Depress Anxiety. 2009;26(3):212-21. doi: 10.1002/da.20549.

PMID:
19194995
15.

Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors.

Dahl AA, Ravindran A, Allgulander C, Kutcher SP, Austin C, Burt T.

Acta Psychiatr Scand. 2005 Jun;111(6):429-35.

PMID:
15877709
16.
17.
18.

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.

Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M.

Curr Med Res Opin. 2007 Feb;23(2):245-50.

PMID:
17288677
19.

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.

Baldwin D, Bobes J, Stein DJ, Scharwächter I, Faure M.

Br J Psychiatry. 1999 Aug;175:120-6.

PMID:
10627793
20.

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.

Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK.

J Clin Psychiatry. 2001 May;62(5):350-7. Erratum in: J Clin Psychiatry 2001 Aug;62(8):658.

PMID:
11411817

Supplemental Content

Support Center